Physician profile
Heather Giannini
NPI 1447646310
$22,366.99
in general payments reported to CMS, 2019-2025
19 companies · $22K in 2025
The $22K reported for 2025 was more than what 95% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $286 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $8,500 · Consulting Fee: $5,652 · Honoraria: $5,250 · Food and Beverage: $2,164 · Travel and Lodging: $801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $8,500.00 |
| Consulting Fee | $5,652.00 |
| Honoraria | $5,250.00 |
| Food and Beverage | $2,163.62 |
| Travel and Lodging | $801.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inogen, INC. | $18,885.15 | 2025 | Inogen Rove 6 |
| Genzyme Corporation | $2,031.98 | 2025 | |
| Glaxosmithkline, LLC. | $461.53 | 2024-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $188.04 | 2024-2025 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $153.17 | 2024-2025 | Dupixent |
| Verona Pharma, INC. | $134.85 | 2025 | Ohtuvayre |
| Harmony Biosciences LLC | $104.83 | 2025 | |
| Insmed, INC. | $90.88 | 2025 | Arikayce, Brinsupri |
| Ani Pharmaceuticals, INC. | $81.60 | 2025 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $53.29 | 2025 | Aralast |
| Philips North America LLC | $36.14 | 2025 | Vest Therapy Und |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.55 | 2025 | Ofev, Jascayd |
| Inspire Medical Systems, INC. | $20.95 | 2025 | Inspire |
| Actelion Pharmaceuticals US, INC. | $16.90 | 2025 | Opsumit, Uptravi |
| Genentech USA, INC. | $16.56 | 2025 | Xolair |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $16.13 | 2024 | Sunosi |
| Viatris Specialty LLC | $14.17 | 2025 | Yupelri |
| Grifols USA, LLC | $13.75 | 2025 | Prolastin-C Liquid |
| United Therapeutics Corporation | $13.52 | 2025 | Tyvaso |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Giannini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.